List of Excipients in API capmatinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing capmatinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | TABRECTA | capmatinib | 0078-0709 | CELLULOSE, MICROCRYSTALLINE | 2035-07-22 |
| Novartis Pharmaceuticals Corporation | TABRECTA | capmatinib | 0078-0709 | CROSPOVIDONE | 2035-07-22 |
| Novartis Pharmaceuticals Corporation | TABRECTA | capmatinib | 0078-0709 | FERRIC OXIDE RED | 2035-07-22 |
| Novartis Pharmaceuticals Corporation | TABRECTA | capmatinib | 0078-0709 | FERRIC OXIDE YELLOW | 2035-07-22 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for capmatinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
capmatinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
capmatinib drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
capmatinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
capmatinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
capmatinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
capmatinib drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
capmatinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
capmatinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
capmatinib drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
capmatinib drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
capmatinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
capmatinib drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
capmatinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
capmatinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Novartis Pharmaceuticals Corporation | capmatinib | 0078-0709 |
| >Company | >Ingredient | >NDC |
capmatinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch